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Abstract
Aminoquinolines are important class of drugs that have been used for malaria chemotherapy for
centuries. However, long-term exposure to these drugs leads to extensive spread of drug
resistance. As such, modified chloroquinoline derivatives are being studied as alternative
antimalarial agents with the possibility to overcome drug resistance associated with chloroquine
analogues.
In this study, 15 aminoquinoline derivatives that are linked by a 1,4-disubstituted 1,2,3-triazole
ring to an ethyl and propyl carbon spacer with a distal amine motif were designed and
synthesized as novel antimalarial agents using the Cu(I)-promoted Huisgen reaction. The
compounds have been synthesized from the 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine alkyne
precursor and the azides of ethyl and propyl amino moieties using a 1,3-dipolar cycloaddition-
coupling in the presence of CuI catalyst to obtain moderate to good yields (53 – 85%). These
compounds have been characterized by the combination of NMR, ESI+ HRMS and IR
spectroscopic methods.
The antiplasmodial activity of the compounds was investigated in vitro against P. falciparum
strain NF54 using chloroquine as a reference drug together with a standard antimalarial drug
artesunate. Of the 15 novel chloroquinoline derivatives, 11 have demonstrated to possess
promising potency by way of the inhibition concentrations less than 250 nM with the lowest
being 28 nM. The observed activities have been ascribed to the overall modifications such as the
introduction of a triazole linker and changing of carbon chain length as these were the variables.
The compounds are accordingly under further biological investigations and only the chloroquine
sensitive results are reported in this work.
Stellenbosch University  http://scholar.sun.ac.za
iii
Acknowledgements
I listened to Albert Einstein telling me, “Any man who can drive safely while kissing a pretty girl
is simply not giving the kiss the attention it deserves.” I could have not done this work without
the following contributions;
First and foremost, I thank my supervisor Professor Williem van Otterlo for his sterling guidance
in this work, but most importantly for your inconvenient time schedule that you have spent
reading and making the incisive comments about this thesis. These have played a significant role
both in shaping the content and the presentation of my arguments in this work.
I extend my gratitude to the co-supervisors, Dr Margaret Blackie and Dr Stephen Pelly, whose
efforts are highly distinguished with gratefulness. Dr Blackie, with whom the biological
investigation of our target compounds have had valuable results and Dr Pelly for the important
discussions that have made me learn.
The labwork would have not been better without the Group of Organic and Medicinal Chemistry.
I thank everyone especially the colleagues in 2020 & 2021; Mohammed Hassam, Abu Taher,
Tanya Mabank, Leandi van der Westhuizen, Ronnel Muller and Jaco de Jagger whom we have
shared joy and cheerlessness.
To my family, the support and courage that I ever receive, stimulates me daily. To my friends
and brothers, Tiro your hospitality and warm welcome into the Cape has been tremendous, and
Kebitsamang thanks for the Chinese talents.
To Else Malherbe, Dr Jaco Brand for running my uninterrupted NMR samples, you ever tireless
NMR spectra analysis has been very valuable. To Dr Marietje Stander and Hiten Fletcher, the
mass spectral analysis of my samples has also been great. To Raymond and Mary, I thank you
for your unfailing support in the lab.
I also thank the NRF for the financial assistance that has made this study possible, without the
support this work would have been a dream. To the Stellenbosch University, I extend my
Stellenbosch University  http://scholar.sun.ac.za
iv
gratitude for studying with you. Thanks to the Pharmacology division of the University of Cape
Town for the biological evaluation of the compounds.
Big thanks to Yahew.








Brief background introduction and research objectives ............................................................1
1.1 General introduction...............................................................................................................2
1.2 Research objectives ................................................................................................................7
Chapter 2
Literature review: Antimalarial activity of aminoquinoline derivatives, chemotherapeutic
treatment of malaria and the synthesis of antimalarial agents ...............................................10
2.1 Molecular mechanisms of action for CQ analogues and resistance.....................................11
2.2 Structure function relationships in CQ derivatives ..............................................................12
2.3 Reversed CQ resistance compounds ....................................................................................17
2.4 Chemotherapy of malaria .....................................................................................................18
2.5 Rationale for selecting 1,2,3-triazoles as linkers..................................................................21
Stellenbosch University  http://scholar.sun.ac.za
vi
2.6 New generation antimalarial agents .....................................................................................23
2.7 Click chemistry ....................................................................................................................24
2.8 Copper(I)-catalysed alkyne-azide 1,3-cycloaddition reactions ............................................25
Chapter 3
Results and discussion; Synthetic methods and in vitro antimalarial activity .......................28
3.1 Target compounds ................................................................................................................29
3.2 Synthesis of the amino chloroquinoline alkyne precursor (1) .............................................30
3.3 Synthesis of lateral chain aliphatic azides............................................................................36
3.4 Functionalization of the aliphatic azides with amine groups ...............................................37
3.5 Synthesis of the 1,4-disubstituted 1,2,3-triazole-linked chloroquine derivatives ................44
3.6 Structural elucidation of the final CuAAC compounds .......................................................47
3.7 Antimalarial activity.............................................................................................................53
Stellenbosch University  http://scholar.sun.ac.za
vii
Chapter 4
Summary, conclusions and recommendations .........................................................................57
4.1 Summary and conclusion .....................................................................................................58
4.2 Recommendations ................................................................................................................59
Chapter 5
Experimental data; chemical synthesis and in vitro biological investigations .......................60
5.1 General methods...................................................................................................................61
5.2 Chemical synthesis ...............................................................................................................62
5.2.0.1 7-Chloro-N-(prop-2-yn-1-yl)quinolin-4-amine (1) ................................................62
5.2.0.2 Ethane-1,2-diyl dimethanesulfonate (2a)...............................................................62
5.2.0.3 Propane-1,3-diyl dimethanesulfonate (2a′) ...........................................................63
5.2.0.4 2-Azidoethyl methane sulfonate (3a).....................................................................63
5.2.0.5 3-Azidopropyl methane sulfonate (3a′) .................................................................64
5.2.0.6 1-(2-Azidoethyl)piperidine (4b) ............................................................................64
5.2.0.7 1-(3-Azidopropyl)piperidine (4b′) .........................................................................65
5.2.0.8 1-(2-Azidoethyl)pyrrolidine (4c) ...........................................................................65
5.2.0.9 1-(3-Azidopropyl)pyrrolidine (4c′)........................................................................66





5.2.1.3 4-(3-Azidopropyl)morpholine (4e′) .......................................................................67
5.2.1.4 General procedure for alkylation of N-(benzyl or phenyl)amine (4f – 4h′) ..........68
5.2.1.5 N-(2-Azidoethyl)-N-methylaniline (4f) .................................................................68
5.2.1.6 N-(3-Azidopropyl)-N-methylaniline (4f′) ..............................................................68
5.2.1.7 2-Azido-N-benzyl-N-methylethanamine (4g) ........................................................69
5.2.1.8 3-Azido-N-benzyl-N-methylpropan-1-amine (4g′)................................................69
5.2.1.9 2-Azido-N,N-dibenzylethanamine (4h) .................................................................70
5.2.2.0 3-Azido-N,N-dibenzylpropan-1-amine (4h′) .........................................................70




5.2.2.2 5-(3-Azidopropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine (4i). ..........................72





























Stellenbosch University  http://scholar.sun.ac.za
x
methyl)quinolin-4-amine (6h) ................................ ................................ ...........................81
5.2.3.7 7-Chloro-N-((1-(3-(dibenzylamino)propyl)-1H-1,2,3-triazol-4-yl)
methyl)quinolin-4-amine (6h′) ................................ ................................ ..........................82
5.2.3.8 7-Chloro-N-((1-(2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)
ethyl)-1H-1,2,3-triazol-4-yl)methyl)quinolin-4-amine (6i) ................................ ...............82
5.3 In vitro antimalarial activity investigations. ................................ ................................ ............83
5.3.1 Quantitative assessment of antiplasmodial activity ................................ ..................83
References ................................ ................................ ................................ ................................ .....88
Supplementary information
1H NMR spectra ................................ ................................ ................................ .............................96
1H NMR spectra for compounds 2a – 6i................................ ................................ .........97 – 133
13C NMR spectra................................ ................................ ................................ ..........................134
13C NMR spectra for compounds 2a – 6i................................ ................................ ......135– 171
1H – 1H Homonuclear correlations ................................ ................................ ..............................172
1H – 1H COSY for compound 6c ................................ ................................ ....................173
1H – 13C Heteronuclear correlations ................................ ................................ ...........................174
gHSQCAD for compound 6b′ ................................ ................................ .......................175
gHMBC for compound 6b′ ................................ ................................ ............................176
ESI+ HRMS spectra ................................ ................................ ................................ ...........177 – 203
IR spectra for compounds 2a – 6i ................................ ................................ ......................204 – 240
Stellenbosch University  http://scholar.sun.ac.za
xi
List of figures
Figure 1.1.1 Three main categories of antimalarial drugs and examples thereof ...........................4
Figure 1.1.2 Historical perspective of aminoquinoline drugs discovery. .......................................6
Figure 1.2.1 A representative structure for a library of triazole-linked CQ derivatives .................8
Figure 2.1.1 Proposed molecular mechanisms for CQ mode of action and resistance.................12
Figure 2.2.1 Shortened carbon chain series of CQ analogues that are active
against CQ resistant P. falciparum strains .......................................................................13
Figure 2.2.2 Metabolic N-dealkylation of CQ antimalarial drug. .................................................14
Figure 2.2.3 Increasing metabolic stability and bioavailability of CQ analogues ........................15
Figure 2.2.4 AQ, a CQ derivative metabolic transformation and toxicity....................................15
Figure 2.2.5 Linker variants in reversed CQ resistance compounds ............................................16
Figure 2.3.1 Some known chemosensitizers for CQ resistance reversal ......................................17
Figure 2.3.2 Structural motifs recognised as CQ reversal agents .................................................18
Figure 2.4.1 Antimalarial drugs and a number of antibiotics used for antimalarial
combination therapy..........................................................................................................19
Figure 2.4.2 First triple combination antimalarial drugs employed against P. falciparum. .........20
Figure 2.5.1 The 1,2,3-triazole structure and an example of a triazole-linked
CQ-chalcone hybrid compound. .......................................................................................22
Figure 2.7.1 Triazole formation via the Huisgen 1,3-dipolar cycloaddition reaction...................24
Figure 2.7.2 The 1,3-dipolar azide mesomeric structures.............................................................25
Figure 2.8.1 Regioselective transformations of the Huisgen reaction under
Stellenbosch University  http://scholar.sun.ac.za
xii
ruthenium and copper metal catalysis ................................. ................................ ..............25
Figure 2.8.2 Stepwise CuAAC reaction between terminal azides and alkynes . ...........................27
Figure 3.1.1 Triazole-linked chloroquinoline target compounds ................................ ..................29
Figure 3.2.1 Synthesis of 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine. ................................ ...30
Figure 3.2.2 pTSA catalysed N-alkylation of 4,7-dichloroquinoline................................. ...........33
Figure 3.2.3 Structural elucidation of 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine (1)............34
Figure 3.3.1 Synthesis of the azidomesylate intermediate precursors. ................................ ........37
Figure 3.4.1 A general template for the synthesis of aminoalkyl azides . ................................ .....38
Figure 3.4.2 Synthesis of 5-(3-azidopropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine..................41
Figure 3.5.1 Synthesis of the triazole-linked chloroquinoline derivatives
via CuAAC reaction ................................ ................................ ................................ .........44
Figure 3.6.1 A representative characterisation of 6f' by 1H NMR and
13C NMR spectroscopic methods. ................................ ................................ .....................48
Figure 3.6.2 1H-1H COSY correlations for compound 6c................................ .............................49
Figure 3.6.3 gHSQC  spectroscopy for 1JC,H correlations for compound 6b'.. ...........................51
Figure 3.6.4 Multiple bond correlations (gHMBC) for 1H –13C NMR spectra
of compound 6b'. ................................ ................................ ................................ ...............52
Figure 3.6.5 Bond cleavage with charge migration for 6g under ESI+ HRMS.............................53
Figure 3.7.1 In vitro antiplasmodial activity of triazole -linked chloroquinoline
derivatives 6b – 6i against NF54. ................................ ................................ .....................55
Stellenbosch University  http://scholar.sun.ac.za
xiii
List of tables
Table 3.2.1 The attempted experimental conditions for N-alkylation
of 4,7-dichloroquinoline ...................................................................................................32
Table 3.4.1 The synthesis of aminoalkyl azides and the product yields .......................................39
Table 3.4.2 N-alkylation of 10,11-dihydro-5H-dibenzo[b,f]azepine ............................................42
Table 3.5.1 The product yields of the respective triazole-linked chloroquinoline derivatives .....45
Table 5.3.1 Antiplasmodial activity of triazole-linked chloroquinoline
derivatives against CQ-sensitive NF 54............................................................................84




This thesis is divided into five chapters. The first chapter consists of the background introduction
to the impact of the disease malaria, then motivates and explains why the research question as to
why synthesizing structurally novel aminoquinoline antimalarial drugs is important. The research
objectives that this work is intended to achieve have been listed in this chapter.
The second chapter is a review of the previous research work in the subject research area related
to antimalarial drugs and chemotherapy but leans towards the aminoquinoline drugs which are
more significant in this study. The basic antimalarial biology of chloroquine analogues, an
aminoquinoline derivative has been added to stress the importance of current understanding of
drug resistance and developing the alternative antimalarial agents in an effort to overcome drug
resistance.
The third chapter specifically discusses and analyses the successes and failures that have been
encountered in the course of this work. It elaborates on the important experimental findings
which which are in line with this work, mainly the chemistry of the synthetic work. The
biological study performed in this work was intended to assess the potential of the synthesized
compounds to inhibit the antimalarial activity and as such the discussion of antimalarial activity
has been catered for in brief, and not to primarily formulate the biological reasons for the
outcome.
The fourth chapter gives the summary and a conclusion of this study finding, the limitations of
the methods employed, and suggests the implications based on the obtained results. Finally, the
last chapter gives the detailed experimental methods as well as the spectrometric data collected
during the analyses.
Numbering of captions and interpretations of spectroscopic data
Due to a variable number of figures per subtitle, the captions for figures and tables have the
extended digit that displays the count of the figure or a table. The numbering of atoms in the
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chemical structures is unconventional but the same numbering sequence has been maintained for
the spectral references of the compounds.
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Chapter 1
Brief background introduction and research objectives
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1.1 Background introduction
The disease malaria is a haematozoan infection caused by sporozoites, transmitted by female
Anopheline mosquitoes.1 It is a pernicious and most deadly parasitic infection whose impact ranks
it the second cause of death in the African continent, after HIV/AIDS related infections. In
addition, it is globally a leading cause of morbidity and mortality,2 mainly in the tropical and
subtropical regions where this disease is endemic. It is now over a century since a Nobel laureate
Robert Ross, in his pioneering work of malaria parasite transmission, considered malaria as a
“million-murdering death”3 and today the disease continues to wreak havoc on millions annually.
In 2010, the human burden caused by malaria approximated 216 million episodes in different
territories around the world with most occurrences in sub-Sahara Africa affecting children without
a protective immunity.4
The nature of the burden caused by the disease malaria is a result of diversity in the parasite host
species (Plasmodium falciparum, P. vivax, P. malariae, and P. ovale and P. knowlesi) that are
responsible for the human malaria.5-6 Among these species, P. falciparum is responsible for the
lethal human malaria; obstruction of the blood vessels of vital organs, premature delivery of
infants, and the worst problem of developing resistive genetic mutations to antimalarial drugs.7-8
The emergence and spread of resistant parasite is a therapeutic challenge that has undermined
generations of antimalarial drugs and the current grim death rate statistics could even rise higher
should the resistance to the existing drugs develop further. The life-cycle of malaria causing
parasites and their developmental stages are complex, each with a preferred cell-target in different
hosts such as mosquitoes and humans or macaques, and thus creates a challenge in the
management, control and elimination of the infection.9
The reason for the continued survival of the Plasmodium parasites against antimalarial drugs lies
in their genetic adaptability. The parasites have selective advantage mechanisms over drugs which
are not fully understood, but certainly the parasite undergoes sexual recombination, a process of
genetic cross-over that results in the offspring having different combinations of genes from those
of their parents.10 This meiotic recombination process results in ‘genetic mutations’ that make
parasites less sensitive to antimalarial drugs.11 Clinical experience and experimental evidence
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indicates that drugs are generally effective when first introduced; however, their efficacies are
curtailed by the emergence of resistant parasites. Coupled to the ever-present problem of
controlling the disease vectors, is the lack of an effective vaccine. The problem has stimulated
investigators to overturn the continuously evolving resistant parasites by developing analogues of
once-effective and well-established antimalarial drugs, in addition to the identification of novel
drug targets.
Despite the long-standing global efforts to eliminate malaria,12 no new classes of antimalarial
drugs have been introduced into clinical practice since artemisinin combination therapy (ACT).
Traditionally, antimalarial agents have been classified by the stages that are targeted by the drugs
in the parasite’s life-cycle, but to date the chemotherapy arsenal represents three main structural
categories, namely, quinolines, antifolate and artemisinin derivatives (figure 1.1.1). The primary
discovery of antimalarial drugs began with the alkaloids comprised of a quinoline motif. Since
then, quinoline derivatives such as the aminoquinolines, quinoline-methanols, acridines and others
have evolved from these initial structures. The antifolate is a different class that encompasses
mostly sulfur-containing and aminopyrimidine antimalarial drugs. Finally, the artemisinin
derivatives are sesquiterpene lactone endoperoxides, and currently the World Health Organisation
(WHO) “gold standard” drugs of malaria therapy.
The heterocyclic compounds with a quinoline motif are versatile, with a wide range of
pharmacological activities and continue to be useful for antimalarial drug discovery. They have
been a cornerstone for the synthesis of active antimalarial drugs for several decades and effective
antimalarial drugs such as chloroquine (CQ), mefloquine (MQ), amodiaquine (AQ), pamaquine
(PamQ) and others have been developed (refer to figure 1.1.1a).13 The essence of drug resistance
has had a paradigm shifting effect in defining the molecular basis of antimalarial drug resistance
and its relationship to therapeutic failure as guidance to design new effective antimalarial agents.
The aminoquinoline moiety is the key pharmacophore on which the attachment of various
ionizable amino side-chains have shown to enhance activity via increasing basicity, possible pH
trapping, or as CQ resistance reversal motifs in CQ analogues.
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In a response to a burdensome challenge posed by malaria, the importance of generating new
antimalarial drugs and maximizing therapy by improving the physicochemical properties of drugs
cannot be overemphasized. A design based on the structure activity relationship (SAR) has
reignited interest in discovering novel antimalarial agents by identifying discrete molecular
components with recognition at a given target.13-14 In the process, the biological activity of potent
antimalarial drugs is enhanced by the addition or repositioning of functionalities on a molecular
fragment. The synthetic organic chemistry of antimalarial drugs was overturned in the late 19th
century after William Henry Perkin commenced to synthesise QN in 1856, but failed and the first
total synthesis of quinine was accomplished almost a century later in 1944.15 The end synthetic
chemistry of QN was found to be complex for commercial use and, even to this day, has not been
accomplished on an economic scale.
The addition of an alkylamine side chain functionality to quinoline scaffolds in designing
aminoquinoline antimalarial drugs was a result of Paul Ehrlich’s work in using haematological
stains to diagnose blood diseases, including malaria itself.16 He observed that a synthetic dye,
methylene blue (figure 1.1.2), was effective in staining and poisoning malaria parasites. Ehrlich’s
intensions to enhance stain visibility led to the preparation of methylene blue analogues with
alkylamine chains, in addition, the analogues were found to possess better antimalarial activity.16-
17 On the basis of these observations, the alkylamine chain was viewed as beneficial for the
antimalarial activity and thus the invention of potent antimalarial drugs were discovered through
addition of alkylamine side chains on different quinoline scaffolds, most notably by the chemists
at Bayer (this process is described schematically in figure 1.1.2).8,16,18 Nonetheless, it was only
after the 2002 unveiling of the P. falciparum genome in a joint global effort led by the Wellcome
Trust Sanger Institute,19 that many intricate details about P. falciparum drug resistance were
obtained and significantly provided an opportunity to challenge therapeutic resistance with
modified CQ analogues.
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1.2 Research objectives
The structural function of quinoline antimalarial drugs remains definitively demonstrated. Recent
short chain analogues of CQ have suggested chain variation as a recognition motif to overcome
CQ resistance, explained in detail later in the thesis. The lateral amine functionality is another
distinctive feature that has the ability to “reverse” CQ resistance. In general, modifications on the
alkylamine side chain can be viewed as a feasible prospect to overcome the acquired parasite
drug resistance to aminoquinoline agents. The application of click chemistry for the formation of
a triazole-linked quinoline system, which possesses metabolic stability, to the lateral alkylamine
chain is therefore justified. The perspectives for triazole-linked compounds stand on the threshold
of the new era and the reported triazole pharmacological activity in various bioactive molecules is
also remarkable.
Our particular study is intended at developing potent antimalarial agents through syntheses of new
molecular entities that are structurally unrelated to CQ or AQ on the lateral side chain. Thus, we
aimed at the creation of a small library of triazole-linked chloroquinoline derivatives having a
short alkyl chain bearing amino functionalities and determination of the SAR for these
modifications. The derivatives are characterized by an aminoquinoline ring that is linked by a 1,4-
disubstituted 1,2,3-triazole to an ethyl and/or propyl spaced tertiary amino moiety (figure 1.2.1).
The work intends to use a Huisgen-Meldal-Sharpless reaction in creating a covalent triazole
linkage of two molecular units by means of copper(I)-accelerated azide-alkyne 1,3-cycloaddition
(CuAAC). This synthetic method tolerates various functionalized aminoalkyl azides to be
integrated with the aminoquinoline parent compound and gives a broader structural horizon for
exploring basic amines with the possibility of overcoming CQ resistance.
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carry out the 1,3-cycloaddition of azides and alkyne promoted by CuI. The in vitro antimalarial
activity investigations of the synthesized compounds should further assist in determining the SAR
and the application of triazole moiety in the future development of antimalarial agents of
chloroquinoline analogues. Should the introduction of a triazole linker be an important strategy in
the modification of chloroquinoline analogues, it would follow that this moiety can critically
influence pharmacologic bioavailability and potentially reverse CQ resistance. The synthesized
compounds might have potent antimalarial activity, although it should not be ignored that the
compounds can inhibit resistance mechanisms by some, as yet unidentified, protein interactions
that are involved in the efflux of drugs by the malaria parasite.
After the short introduction provided in this section, the next chapter will give a more “in-depth”
look of aminoquinoline derivatives and various strategies involved in their use as antimalarials.
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Chapter 2
Literature review: Antimalarial activity of aminoquinoline
derivatives, chemotherapeutic treatment of malaria and the
synthesis of antimalarial agents.
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2.1 Molecular mechanisms of action for CQ analogues and resistance
The exogenous supply of amino acids from haemoglobin degradation is absolutely essential for
the parasite growth and survival. In the degradation process, toxic haematin moieties are
generated as by-products and are removed by polymerization into an inert haemozoin.23-25 The
haem accumulation is induced by the CQ analogues that bind to haematin moieties leading to
inhibition of haemozoin formation.19 This inhibition of haematin polymerisation vitally sensitises
the parasite and the antimalarial activity is subsequently manifested. Unlike other drug targets,
haematin polymerisation process is non-enzymatic and the drug target remains vulnerable to
drug’s bioavailability.26 The aminoquinoline target, haem-detoxification has been extensively
studied, and continues to remain the most attractive area for developing 4-aminoquinoline
antimalarial agents.25,27
CQ accumulation in the parasite's digestive vacuole (DV) might occur via ion trapping, in other
words, a passive diffusion of a basic CQ across the pH gradient into the acidic vacuole or binding
to active transporters such as ATP or CQ receptors.28 In the DV, CQ becomes membrane
impermeable after di-protonation (CQ2+) and complexes with the intra-vacuolar free haematin or
ferriprotoporphyrin IX (FP) receptor and thus inhibits the formation of crystalline haemozoin. The
resistance of CQ is considered to be modulated by the protein membrane transporters such as P.
falciparum CQ resistance transporters (PfCRT) or ATP-dependent P-glycoprotein homolog-I
(Pgh-1) pumps which decrease drug concentration by way of drug efflux mechanisms.29-30 In
addition, biochemical data in the literature indicates that resistance to CQ is a multi-genetic
phenomenon and affects drug accumulation in the parasite’s food vacuole.17,31
The molecular mechanisms of CQ resistance have remained enigmatic and theoretical models
adopting reduced drug accumulation in the DV or carrier-mediated efflux have received much
attention. The present evidence reveals that CQ resistance is primarily linked to an increased
drug’s efflux as a result of mutations in the metabolite transporter of P. falciparum (PfCRT).
PfCRT is a membrane localized protein in the parasite’s digestive vacuole which is associated
with the drug’s efflux from the site of action in the parasite’s DV.32-33 The key role of PfCRT in
CQ resistance is beyond dispute34 and studies confirming the point mutations in this gene as
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primary determinants of cross-resistance on various antimalarial drugs has been established.35 The
molecular mechanism of CQ mode of action and resistance mechanism is summarized in figure
2.1.1 adapted from the literature.28
Figure 2.1.1 Proposed molecular mechanisms for CQ mode of action and resistance.28
2.2 Structure function relationships in CQ derivatives
The SAR of 4-aminoquinolines has been extensively elucidated in an attempt to restore
antimalarial efficacy and overcome drug resistance. To this end, synthetic medicinal chemistry
has developed a shortened-chain series of CQ analogues, organometallic antimalarial agents and
also the hybrid antimalarial drugs, see figure 2.2.1. These classes of compounds have established
the crucial role of the 7-chloro-4-aminoquinoline ring as well as the lateral side chain nitrogen for
the antimalarial activity.24,36 The significance of alterations on the lipophilic carbon chain of CQ
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The prophylactic use of CQ has been challenged by the widespread CQ resistant strains and has
been replaced by artemisinin derivatives. However, the first signs of therapeutic resistance to
artemisinin are subtle and have been very difficult to analyse.65-66 At the present moment, there is
no convenient surveillance for detecting ACT resistance and the most reliable way is through
rigorous clinical efficacy studies, which are very expensive and often lengthy.67 Clinical evidence
gathered from Western Cambodia has recently warned that the emerging ACT resistance against
the current first-line drugs would be catastrophic to initiatives aiming at global malaria control.66
The Southeast Asia region has, in the past, hatched ACT treatment-resistant malaria that has
spread to the rest of tropical regions around the world.65 It is therefore imperative to prime the
antimalarial pipeline with novel compounds that have been made by the application of facile,
reliable and quick synthetic methods.
2.5 Rationale for selecting 1,2,3-triazoles as linkers
Apart from creating benzyl- or phenyl-linked chloroquinoline derivatives in creating “reversed”
CQ compounds that might exhibit similar cross-resistance susceptibility patterns to AQ, it is
envisaged that a triazole moiety can be used as a scaffold to broaden structural diversity. A 1,2,3-
triazole is a five-membered heterocyclic aromatic system containing three consecutive nitrogen
atoms connected to two carbon atoms in a ring, as illustrated in figure 2.5.1. Triazoles have been
known for over a century68 and are stable to hydrolysis, as well as reductive or oxidative
conditions, as a result of their aromatic stabilization. The triazole moiety is more than just a
passive linker with in vivo metabolic stability69 and rigidity, as it associates readily with biological
targets through hydrogen bonding and dipole interactions.70 It is also an important structural
feature that has inhibition activity against cytochrome p450 enzyme and/or peptide analogue in
many biological compounds.71
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of the malaria chemotherapy is to develop promising compounds that are innovative with
chemical structures and mechanism of action.
2.6 New generation antimalarial agents
In the advent of the organic synthesis of new antimalarial drugs that are affordable, two or more
‘biologically privileged’ pharmacophores can be covalently joined into a single molecule by a
linker.87-88 These derivatized compounds have the potential to offer an effective way of delivering
a drug with favourable synergistic pharmacological activity.13-14 This approach can be regarded as
supplementary to combinations, especially when combination has a marginal benefit that carries a
significant toxicity. The formulation of “linked drugs” carries less risk of combination
pharmacological interactions although inherent negative traits of individual pharmacophores is
still possible.13 This is thus a cheaper development investment in drug discovery, especially where
there are difficulties in sourcing natural metabolites or when the chemistry of synthesis is
complex.
Another basis for hybridization is to exploit receptor binding capabilities by using linkers that can
actively enhance active transport mechanisms and drug bioavailability. This is vital with respect
to designing molecules which are intended to overcome cross-resistance under metabolic
conditions. The 1,2,3-triazoles linkers are logical antiplasmodials as they are lipophilic nitrogen-
containing heterocycles that tend to accumulate into the DV of a parasite.89 A critically important
strategic element in generating such linkers is the reliability of the synthetic chemistry,88 which
must proceed selectively to construct chemically stable bonds in a broad range of functional
groups. For this reason, Kolb, Finn and Sharpless described the ideal class of reactions with
organic transformations that satisfies this criteria, namely click chemistry reactions.90 The
transformations performed with these reactions are versatile and have found applications in
various fields of chemistry, materials, peptides, bioconjugation, radiolabeling of biomolecules for
imaging, and importantly in the advancement of structure-based drug discovery.85,90-91
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To date, for assembling disparate molecular fragments, the CuAAC reaction has demonstrated
several advantages over the uncatalyzed Huisgen reaction.90,104 The application of copper catalyst
significantly lowers the activation-energy barrier and thus accelerates the reaction rate (107 to 108
faster) at room temperature. An important feature is that Cu(I)-accelerated reaction is not affected
by the steric and stereoelectronic influences of the substrates utilised.102,105-106 A variety of
experimental approaches have been effectively carried out with different Cu(I) sources, direct
Cu(I) salts or the in situ reduction of Cu(II) salts, on a myriad substituted alkyne functional
groups.102,106-107
A nitrogenous base or copper ligands are sometimes added to the CuAAC reaction, with the most
commonly used conditions being those reported by Sharpless group.106 Under those conditions, a
catalytic Cu(II) salt and excess molar equivalents of a reducing ascorbate with the amine base
additive are used to couple azides and alkynes with little or no co-solvent. The mechanism of the
CuAAC reaction has been under several in-depth and ongoing investigations. According to kinetic
studies and density functional theory calculations, the reaction is considered to be non-concerted
in nature and proceeds in a stepwise fashion.107-108 The key steps in the reaction are highlighted in
figure 2.8.2. The reaction proceeds by generating the copper(I)-acetylide, which occurs via alkyne
π-coordination with a copper catalyst. The alkyne reactivity is thereby enhanced via a decrease in
the electron density of the sp carbon atom and subsequently the pKa of the acetylene proton is
lowered by about 10 log units.97,109-111 The reaction has been demonstrated to follow a second
order rate law in copper when catalytic quantities are used.110 The intermediate Cu(I)-acetylide
participates in a [3 + 2] dipolar cycloaddition with the azide. Due to a high potential energy
barrier (ca 23.7 kcal/mol) of the 1,3-cycloaddition of azides to the copper(1)-acetylide, the azide
is selectively activated by coordination to the acetylide-copper complex, thus forming a 6-
membered metallocycle ring.109-111 A ring contraction then follows the thermo-neutral ligand
exchange, after which a triazole ring is formed by protonation and release of the copper catalyst.
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
28
Chapter 3
Results and discussion: Synthetic methods and in vitro
antimalarial activity
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The synthesis of 1 has not been reported in the literature before, but the nucleophilic ipso
substitution reactions on 4,7-dichloroquinoline ring system using non-activated primary amines
have been described in established literature methods.113-116 We therefore turned our attention to
the development of this aminoquinoline alkyne precursor 1. A brief assessment of reagents used in
these reactions show that amine nucleophiles play several additional roles, for instance, to basify
and to solvate the reaction media. These methods thus predominantly make use of a large excess
of amine nucleophile, up to 20 molar equivalents, to obtain moderate to good yields of the desired
product (60% – 92%). It should be considered that in our case, the high price of propargyl amine
(5 mL > 1,300 ZAR Sigma Aldrich) would make this atom uneconomical approach extremely
costly. The described literature conditions were however attempted with the initial 2 molar
equivalents of propargyl amine,113 supplemented by another less nucleophilic base to decrease the
amounts of propargyl amine required as described in the paragraphs that follow.
According to the cited experimental methods,113-115 and others reported elsewhere, a mixture of
chloroquinoline and amine is usually homogenised at 80 °C, followed by a heating at reflux or at
elevated temperature, i.e. 120 – 140 °C. Similarly, in our hands, the experiments were stirred at 80
°C for 1 hour during which TLC monitoring displayed formation of the intended product.
However, a follow-up reaction at 120 °C made it clear that at elevated temperature the product
was undergoing decomposition into a brown solid of unknown composition (see table 3.2.1, entry
1). From this observation, it was concluded that higher temperature was detrimental to the
reaction. Decomposition has been demonstrated as a major problem for similar reactions and
milder reaction conditions have often been considered necessary for these reactions to be
successful, i.e. reactions at 85 °C rather than high temperatures.24 In further modifications, the
amounts of supplementary base was increased, but unfortunately the yields obtained were rather
low (refer to table 3.2.1, entries 2 – 6). In addition, it can be deduced from entry 3 from the same
table that a proportional addition of excess propargyl amine, which was believed to perhaps
escape from the reaction medium by vaporisation, did not have a significant impact on the
reaction yield obtained and alternative conditions were thus investigated.
Stellenbosch University  http://scholar.sun.ac.za
32









1) 2 Et3N (0.5) None 80 – 120 Decomposition
2) 2 Et3N (0.5) None 80 – 100 11
3) 2 + 2 Et3N (2.0) None 80 – 85 24
4) 2 Et3N (4.0) None 80 – 85 17
5) 2 K2CO3 (3.0) DMSO 80 – 100 Insignificant
product
6) 2 K2CO3 (3.0)
+ Et3N (2.0)
DMSO 80 – 85 Insignificant
product
7) 2 pTSA (0.1) MeCN 80 – 85 37
8) 2 pTSA (0.1) Dioxane 80 – 85 55 – 63
9) 2 None Dioxane 80 – 85 6
Nucleophilic substitution reactions that proceed slowly at high temperature to give low yields
might be found, in polar aprotic solvents like DMSO, to proceed rapidly and give better yields.
Given the reputable advantages of DMSO in promoting such reactions together with a high
boiling point advantage, it was expected that the yields of 1 would improve, unfortunately under
these conditions, the reaction was found to have hardly progressed even after 24 hours, although
decomposition was not observed (see table 3.2.1, entries 5 – 6).
In these type of reactions, it is known that the chlorine atom generally has poor leaving abilities
when compared to other leaving groups due to strength of the C–Cl bond (D0 ~ 79 kcal/mol).112 In
order to carry out successful nucleophilic substitutions on the ring carrying this leaving group, the
N-heterocycle’s propensity to undergo nucleophilic addition can be enhanced by inducing a
formal positive charge on the ring nitrogen. Thus, N-oxides or N-quinolinium salts are established
promoters of such reactions; nonetheless, N-oxides on quinoline can be viewed as disguised 1,3-
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
35
The most important signals were those of the newly installed propargylic amine group in addition
to the expected aromatic signals for the chloroquine ring. Although amine protons are generally
not considered suitable for diagnostic purposes due to lack of consistency in their shifts, a broad
triplet at 7.8 ppm was assigned to the N–H proton at the γ-position with a J = 5.7 Hz
corresponding to the allylic proton coupling. Moreover, a double of a doublet at 4.1 ppm was
assigned to the allylic protons which were further coupled to the acetylenic proton triplet at 3.2
ppm with a J = 2.4 Hz. These signals were indicative of the successful substitution of the
propargyl amine on the chloroquinoline ring system. 13C NMR spectroscopy was also used to
substantiate the structural elucidation of 1 and the three additional carbon signals were observed:
namely, the high-field shifted carbon signals at 74 ppm and 81 ppm in comparison to the aromatic
carbons (100 – 152 ppm) were characteristic of the sp hybridised acetylene carbons of a terminal
alkyne and the additional carbon signal at 32 ppm provided the evidence of an aliphatic CH2
carbon with an incremental downfield shift due to a proximal nitrogen atom.
In addition to NMR spectroscopy experiments, the positive electron spray ionisation mode in high
resolution mass spectrometry (ESI+ HRMS) was carried out to determine the isotopic mass and
perhaps elemental composition of compound 1. The protonated molecular ions ([M + H]+; m/z)
was the dominant species and the peak with the highest isotopic abundance was customarily
assigned 100%. The determined experimental monoisotopic mass of 1 [M + H]+ = 217.0529 and
was found to be in good agreement with the theoretical 217.0533 and within -1.84 ppm accuracy.
In addition to the molecular ion peak, a peak at m/z 219.0503 with approximate abundance of 27%
was considered to be due to the isotopic 37Cl which has about 24% relative abundance, thus
confirming the atomic composition of 1. Additional small clustered peaks around the base peak
were ascribed to the compositional isotopic masses too.
The IR spectroscopic skeletal vibrations (υ/cm-1) were further used to confirm the important
functional groups: 3391 (NH stretch) was assigned to the aliphatic secondary amine; 3205
(C≡CH) acetylenic proton stretch, 3094 (Ar CH) aromatic protons stretch in the ring, 2963 (CH2)
aliphatic methylene asymmetric stretch; 2019 (C≡C) was a very broad band of acetylene; and a
very weak peak at 1567 frequency further confirmed the (C=C) aromaticity in reference to Ar CH
aromatic protons observed at 3094.
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3.3 Synthesis of lateral chain aliphatic azides
As aforementioned, the azide building blocks were the next requirements for the CuAAC
reactions with compound 1. It was, therefore, necessary to synthesise aliphatic azide spacers
which would later be functionalized with selected amines. This section describes the synthesis that
was followed to obtain azides of ethyl and propyl linear chains. Several detailed models of the
structure function relationships of CQ have established the importance of carbon chain length
variation in restoring the antimalarial efficacy of 4-aminoquinolines.37-38,118 The azides of ethyl
and propyl carbon chain length were therefore synthesized in two steps from ethane-1,2-diol and
propane-1,3-diol starting materials, respectively, using a modified literature procedure.119 The
diols were first converted into their corresponding bis-mesylates using mesyl chloride under basic
conditions in THF as a solvent to afford compounds 2a and 2a′ in good yields, 94% and 99%,
respectively.
The 1H NMR spectra for the compounds were in agreement with the data reported in the
literature.119-120 The chemical structures of 2a – 2a′ were also supported by the IR spectrometry
(υ/cm-1). The intensely sharp peaks at 1176 (S=O) and 1048 – 1045(O–S) distinctively confirmed
the presence of the newly introduced, substituted sulfonate groups. The medium intensity peaks at
2963 – 2933 (CH2) and 2884 – 2789 (CH2) were assigned to the methylene asymmetric and
symmetric stretches while the peaks at 1359 – 1352 (CH bend) were attributed to CH bend
vibrations, respectively, confirming the presence of aliphatic carbon chain. In addition to the
above mentioned peaks, a medium band at 748 (CH rocking), which can only appear in longer and
linear aliphatic chains, was observed in the case of 2a′ to strengthen that 2a′ was of a longer
propyl length (see figure 3.3.1).
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
40
In cases where lower yields were obtained, for instance with 4d and 4d′, it was observed that the
azides were semi-volatile and that most of the product was being lost in vacuo during solvent
removal. The rest of samples were therefore dried by passive evaporation in a vacuumed
desiccator after short treatment with once off vacuum to remove most of the solvent entrapped in
the sample. The majority of synthesized aminoalkyl azides, reported in table 3.4.1, are not
reported in the literature and as such 1H NMR, 13C NMR, ESI+ HRMS and IR spectroscopic
methods were used to confirm the structures of these compounds. Depending on whether the
amine functional group was aliphatic or aromatic, the characteristic signals were verified by the
appropriate spectroscopic methods; however, constantly common was the important azide peak at
frequency 2093 – 2136 cm-1 in the IR spectra.
The 1H NMR spectra of compounds 4b – 4i varied from one compound to the other, but the
aliphatic azide chain signals remained almost unchanged (see figure 3.4.1). The protons in the α-
position with respect to the azide at 3.3 – 3.8 ppm were equally split into a triplet signal by the
neighbouring protons with a J-value of 6.3 – 7.9 Hz which denoted the free rotating aliphatic
carbon chains. In the case of the propyl chain, an additional quintet at 1.7 – 1.8 ppm with a similar
coupling constant, was observed, in the absence of other overlapping protons signals.
The efforts to achieve substitution with a pyrrolidine group (refer to table 3.4.1, entries 4c and
4c′) using the described conditions (MeCN, K2CO3, Δ)119 proved to be futile presumably as a
result of assumed decomposition. During the reaction progress, an instant change of colour to a
brown solution was considered to indicate the unidentified side reactions, in this particular case.
An alternative method was therefore employed123 and the reagents were thus homogenised at 0 °C
first followed by overnight heating at reflux to afford compounds 4c and 4c′ in good yields (64 –
73%). Furthermore, the N-alkylation of aromatic amines was promoted with potassium iodide
(KI) in the light of their poor basicity, low nucleophilicity and problems associated with steric
effects (see table 3.4.1, entries 4f – 4c′). Traditionally, KI is known to promote substitutions via
the Finkelstein reaction124 in which a less labile halide or halide equivalent sulfonate is substituted
by a better leaving iodine which is subsequently displaced by the amine.
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amines are known to be promoted by heating but such efforts were inefficient in our hands (refer
to table 3.4.2, entries 1 – 3). Moreover, mesylate esters are good electrophiles for substitution
reactions but can also undergo efficient elimination when reacted under strong base conditions.
With this information at hand, it was realised that elimination reaction was the major side-reaction
taking place (see table 3.4.2, entries 3 – 4) and that the sulfonate leaving group also favoured
elimination over substitution under these conditions.
At this point, the sulfonate leaving group was swapped for a halide and 1-bromo-3-chloropropane
was used as an alkylating agent. 10,11-Dihydro-5H-dibenzo[b,f]azepine was thus deprotonated
using nBuLi in THF solvent (refer to figure 3.4.2 ); however, alkylations under these conditions
gave the unwanted N-allyl product (refer to table 3.4.2,entry 5), obviously due to a subsequent E2
elimination. Reaction rate studies of similar reactions by Collum and co-workers described the
formation of various diphenyl lithium aggregates to be the primary determinants of N-alkylation
in the THF solvent.126 In neat THF solvent, the alkylation rates exhibited fractional dependence on
the amide, first order on the alkyl halide and a seventh order dependence on THF.126-127 The
alkylation success thus changes with the degree of amide solvation and aggregation states, and
these factors thus influence the ratios of N-alkylation versus E2 elimination.
Table 3.4.2 N-alkylation of 10,11-dihydro-5H-dibenzo[b,f]azepine
Leaving group Solvents (Base) Temp °C Product (5a:5a′)
1. -OMs MeCN (K2CO3) 80 – 110 Not observed
2. -OMs Toluene (tBuOK) 80 – 140 Not observed
3. -OMs DMF  (NaH) RT – 140 Not observed
4. -OMs DMF  (NaH, nBuLi) 0 – RT Insignificant product
5. -X THF (nBuLi) 0 – RT 43%, 5a
6. -X THF: C6H6 (1:1; nBuLi) RT – 50 Insignificant prod.(5a′)
7. -X THF:C6H6 (1:1; nBuLi) 0 – RT 44%, 5a/5a′ ~(5:1)
8. -X THF:C6H6 (1:4; nBuLi) 0 – RT 47%, 5a/5a′ ~(1:1)
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Under this paradigm, SN2/E2 selectivity would then show propensity to favour SN2 at low THF
concentrations. However, in an attempt to perform the reaction using Collum’s conditions at
50°C, an insignificantly low amount of N-alkyl product was formed (see table 3.4.2, entry 6). The
satisfactory SN2 product 5a′ was however isolated from an approximated 1:1 product ratio, when
employing 20% THF in benzene solvent, and when the reaction was carried out at 0 °C – RT
(refer to table 3.4.2, entry 7). From the chemistry point of view, the N-allyl product, 5a, could be
converted into a desired terminally substituted azide via the known anti-Markovnikov
hydroazidation in the presence of catecholborane,128 but in our case the direct halide substitution
of 5a′ with NaN3 to produce 4i (61% yield) was followed. The structural analysis of 4i was
carried out using the same spectroscopic methods described earlier in this section.
The identification of isolated compounds 5a and 5a′ was established clearly by means of 1H NMR
and 13C NMR spectroscopy. The structure of 5a was distinct since it had a unique ABX allylic
splitting pattern at 5.1 – 5.8 ppm together with a diagnostic vinylic proton coupling system (2JH,H
= 5.7 Hz, 3JH,H cis = 10.3 Hz, and
3JH,H trans = 17.3 Hz) to both cis and trans protons which could be
differentiated from their J-values. In order to ascertain whether 5a′ was bromo- or chloro-
substituted, 1H NMR spectroscopy was again crucial in differentiating the two compounds using
the protons chemical shifts. The protons at the α-position to Cl resonated at a much higher
frequency of 4.4 ppm in 5a′ compared to those of Br at 3.6 ppm. The ESI+ HRMS spectra data
also supported the 1H NMR spectral evidence.
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reaction was carried out and it was found that the intended product deteriorated until no product
spot could be identified on the TLC. The 1,4-disubstituted triazole-linked chloroquinoline
products (see table 3.5.1) were very polar, but fortunately a solvent system consisting of 10%
methanol in acetone successfully developed analytical TLC for the compounds, at least two TLC
runs in some cases. However, the by-product did not move from the TLC baseline with this
mobile phase and increasing mobile phase polarity often resulted in poorly resolved TLC due to
trailing.
3.6 Structural elucidation of the final CuAAC compounds
The structures of all the compounds obtained, 6b – 6i, were established by 1H NMR, 13C NMR,
ESI+ HRMS and IR spectroscopic methods.  A representative characterisation of compound 6f' is
described below. In a deuterated chloroform, a similar 1H NMR and 13C NMR spectra pattern of
the chloroquinoline ring (described under section 3.2) was observed for all the compounds with
the exception of signal migrations and swapping of the chemical environments between H-5 and
H-8 (refer to figure 3.6.1). The order of chemical frequencies for H-5 and H-8 were swapped in
the synthesized triazole derivatives as compared to the previously characterised aminoquinoline
alkyne 1. The H-5 doublet had migrated to a lower frequency at 7.8 ppm in comparison to the
initially observed 8.2 ppm in 1. In addition, the triazole proton H-5' appeared as a singlet in all the
cases although a weak spatial coupling to the neighbouring protons was observed, as discussed
later.
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1,4-disubstituted triazole-linked chloroquinoline derivatives, and not the corresponding 1,5-
derivatives.
To ascertain the 1,4-disubstitution and connectivity around the triazole ring, NMR spectroscopy
experiments utilising gradient selected heteronuclear correlations over a single bond (gHSQCAD)
and multiple bonds (gHMBC) were conducted for the compound 6b'. Having confirmed the
proton correlations from the COSY NMR spectroscopy experiment, the gradient selected
HSQCAD and HMBC spectroscopic experiments were used to trace the carbon skeleton of the
identified triazole-linked chloroquinoline derivative. The HSQCAD spectra was used to
selectively determine the single coherence between protons and carbons, 1JC,H. From this
experiment the carbon carrying the triazole proton (C-5') was clearly identified from the rest of the
aromatic carbons, whose signals overlapped heavily (refer to figure 3.6.3). As it can be deduced
from figure 3.6.3, it would have been very difficult to also distinguish C-5 at 121.3 ppm from the
C-5' triazole carbon at 122.1 ppm. These two carbons could easily be misinterpreted when using
normal APT and DEPT spectroscopic methods because of their equivalence on the 13C NMR
spectra. Furthermore, the regioisomeric nature of the triazole isomer could already be partly
deduced at this point when taking into consideration the chemical shifts of C-5' triazole carbon at
122 ppm versus C-2 at 152 ppm of the chloroquinoline. Because these chemical shifts must be
controlled by the pyrrole or the pyrimidine character of the neighbouring nitrogen atoms, it was
obvious that the triazole C-5 resembled the pyrrole character which reserved for the 1,4-
regiosomers that are unsubstituted at this position.
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and an artesunate standard was undertaken. The test compounds were evaluated on the asexual
blood cycle stages, namely merozoites → trophozoites → schizonts that produce more merozoites
of malaria parasitic infection.131 At this stage, the blood cells are invaded and the symptoms of
malaria infection become evident in a person suffering from malaria infection as the cycle
continues. These blood schizonts can be destroyed by drugs such as CQ to terminate a continuous
infection that causes red blood cell invasion by the merozoites.
The human malaria parasites rely on the anaerobic carbohydrate metabolism, i.e. glycolysis, for
the supply of glucose and the pLDH enzyme which is produced during the process has been used
as an index of reduction in the parasite multiplication.132 The parasite lactate dehydrogenase
(pLDH) levels133 have been used in this study to assess P. falciparum strain NF54 sensitivity as a
marker of antimalarial activity.
The synthesized compounds exhibited notable antiplasmodial activity with few exceptions and the
data for the test compounds are illustrated in figure 3.7.1. Among the 15 tested compounds, 11
exhibited potent antimalarial activity below the 250 nM concentration. The highest concentration
beyond which the exposed parasites had no measurable inhibition in the blank was out of
measurable range and it is not shown. In addition, the inhibition activity of compound 6h could
not be measured under the concentration range investigated and a default IC50 value was
extrapolated from the highest test concentration. Compound 6e had a very low antiplasmodial
activity but the complementary compounds 6e′ and 6h′ displayed good inhibition activities below
250 nM. The observation automatically made compounds 6e and 6h the qualified experimental
outliers since the inhibition effect of the two compounds needed to produce 50% maximal
inhibition effect was not certainly quantifiable under the concentration range investigated.
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Figure 3.7.1 In vitro antiplasmodial activity of triazole-linked chloroquinoline derivatives 6b – 6i
against NF54.
Compounds 6f and 6f′ are a related pair that had lower activity status with IC50 values over 250
nM. These phenyl amine analogues, 6f and 6f′, with activity in the range 247 – 587 nM were
clearly distinguished from the structurally related benzyl amines, 6g′ and 6g with activity range 32
– 163 nM. On some occasions the data for 6b – 6c′, 6d′ and 6g′ compared closely to the standards;
CQ, artesunate, and MMV 390048 (antimalarial drug in phase I clinical trials launched by the
university of Cape Town), with the IC50 values being below 100 nM. Apart from 6f and 6f′, the
rest of aryl amine substituted compounds possessed inhibition activities below 250 nM while the
aliphatic amines generally exhibited good inhibition activity below 100 nM, with the exception of
the already mentioned outliers 6e and 6h. Compounds 6b and 6b′ were the aliphatic piperidinyl
compounds with IC50 values in the range of 27 – 42 nM. The activity unfortunately did not reveal
conclusive information on the variation of carbon chain length. The influence of chain length on
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the activity varied between the individual pairs, but on average the aliphatic amine derivatives
bearing an ethyl spacer were more active (6b – 6d′) than their counterparts with a propyl spacer.
On the contrary, the activity order was reversed in the series of aryl amines, the compounds with a
propyl spacer demonstrably being more active (6f – 6h′).
Studies by Krogstad and co-workers, on the impact of the length of aliphatic chains in antimalarial
activity have demonstrated that changes in the length have minimal impact on improving the
activity in CQ sensitive strains of P. falciparum.37,118 These observations are, however, in
agreement with our results although the impact cannot be directly linked to the change in chain
length as the triazole ring is also an important variable concerning the observed activities of the
compounds. However it is tempting to suggest that the modifications, either chain length or
incorporation of a triazole ring, perhaps constitute a primary recognition motif for the
undiminished antimalarial activity of the compounds. The findings are valuable because
homologation in the side chain alone alters the lipophilic character and thus is expected to affect
the spatial relationship of functional groups in the molecule, and thereby influencing activity.
Other studies, from the literature, on CQ resistance reversal activity have provided substantial
insights into the function of the lateral chain amine.29 The essential features such as hydrogen
bond acceptor capabilities, lipophilicity, and tertiary nitrogen atoms have been found to be
optimal for activity in some CQ analogues.52,134 Therefore the distal amine functionalities have
also been associated with CQ reversal activity and on such grounds the SAR profiles of the
triazole-linked CQ derivatives will have to be substantiated with the CQ resistant strains assays
which are currently in progress. As aforementioned, asexual recombination of malaria parasites
plays a crucial role in the development of treatment-resistive P. falciparum malaria. Thus the
current inhibition activity results serve as a valuable prognostic indicator of the application of
compounds containing a triazole linker in the restoration of antimalarial efficacy of CQ analogues.
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Chapter 4
Summary, conclusion and recommendations
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4.1 Summary and conclusion
The primary objectives of this work were successfully achieved. Synthesis of the chloroquinoline
amino alkyne precursor 1 was successfully accomplished in a moderate yield of 63%. The azide
building blocks were then synthesized in various yields (34 – 73%) and were obtained using
different reaction routes as described in the dissertation. The triazole-linked chloroquinoline
derivatives were then synthesized from chloroquinoline amino alkyne 1 and various aminoalkyl
azides building blocks using a modular CuAAC reaction to obtain the compounds 6b – 6i within
30 – 90 minutes at room temperature, in moderate to good yields (53 – 85%). The characterisation
and structural elucidation of the novel compounds was carried out using inter alia 1H NMR, 13C
NMR, and ESI+ HRMS spectroscopic methods supported by the IR spectra. The antiplasmodial
activity of the synthesized compounds was lastly investigated on the asexual blood stages of P.
falciparum strain NF54. The in vitro biological investigations have showed the potential of a good
antiplasmodial activity in some compounds which compared closely in activity to the standard
antimalarial drugs.
In conclusion, a library of 15 4-aminoquinoline compounds, linked to a variety lipophilic aliphatic
amino side chains by a 1,4-disubtituted 1,2,3-triazole has been created using the versatile CuAAC
reaction. The compounds were synthesized in moderate to good yields and the in vitro
antiplasmodial activity of the compounds is promising. The overall results have demonstrated that
triazole-linked CQ analogues are potential inhibitors of P. falciparum with undiminished
antimalarial activity. As there was more than one variable in the design of our compounds,
including the introduction of a triazole linker as well as variation in chain lengths, the observed
activity is attributable to the overall contribution of these modifications. Therefore, the results
reported herein should be useful in guiding future efforts to discover CQ analogues with increased
antimalarial activity. Consequently, the reported compounds are currently undergoing the in vitro
antiplasmodial investigations.
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4.2 Recommendations
Despite moderate to good synthetic results of the compounds, it has been observed that the use of
excessive amounts of Cu(I) in the catalysis of amine bearing compounds can be disadvantageous
even though it provides shorter reaction times and quick generation of compounds. Therefore,
such syntheses should in future, be investigated using different Cu(I) sources at substoichiometric
quantities. It has been shown that the triazole-linked chloroquinoline derivatives posses the
antimalarial activity which justifies the compounds to be recognised as antimalarial agents.
In the recent literature, the investigations concentrating on the mode of action of CQ analogues
and new targets for these compounds are evident. In terms of the latter research, these novel
targets include proteases that are involved in haemoglobin degradation.33,135 These findings
necessitate further investigations as to whether there is an additional role that the triazole ring can
play to potentially affect the antimalarial activity when used as a linker to various haematin
complexing scaffolds. The inhibition of haemozoin formation is likely the mechanism by which
the synthesized compounds exerted their antimalarial activity. However, a β-haematin inhibition
assay which must reveal correlations between parasite inhibition and haemozoin formation is
necessary to determine the mode of the antimalarial activity.136 This should further serve in the
SAR evaluation of the generated triazole-linked aminoquinoline derivatives in development on
novel antimalarial compounds.
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Chapter 5
Experimental data; chemical synthesis and in vitro biological
investigations
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5.1 General methods
Unless otherwise stated, all the reactions were carried out under inert nitrogen atmosphere in dried
solvents using conventional distillation methods.
The 1H, 13C, COSY, gHMBC, and gHSQCAD NMR spectra were recorded on Varian Unity Inova
spectrometers with 1H frequency of 400MHz or 300 MHz, and 13C frequency of 75 MHz or 150
MHz. All spectra were obtained on a 5mm dual broad band PFG probe with a probe temperature
of 25 °C. The chemical shifts (δ) are reported in ppm relative to internal solvent peaks and the
coupling constants (J) were measured in Hertz. The 1H signals splitting pattern abbreviation were
as follows: singlet (s), (doublet), triplet (t), quartet (q), quintet (p) doublet of doublet (dd), triplet
of a doublet (td),multiplet (m), and a broadened signal was prefixed (br).
The fingerprint identification of specific functional groups was achieved by assigning of group
frequencies (cm-1) of particular peaks within the IR spectra. The IR spectra were obtained from
Nexus infra-red Pc spectrometer equipped with a DTGS KBr detector and the percentage (%)
transmittance was recorded against the wave length (υ/cm-1) for the reported signals. The high
resolution mass spectra were recorded on electrospray ionisation on positive mode (ESI+) using a
quadrupole MALDI-TOF LC/MS instrument.
Preparative column chromatography was carried out on a silica gel 60; 70 – 230 mesh ASTM,
Fluka. Thin layer chromatography (TLC) was performed using pre-coated aluminium silica gel
plates (60F254 Merck) and the developed TLCs for the compounds were viewed after staining or
under UV (254nm) light. Aliphatic mesylate intermediates were detected by means of KMNO4
stain and their corresponding azides were visualized after a contrast Ruhemann’s purple colour
was developed with a ninhydrin stain following a TLC azide to amine reduction.121
Finally, the melting points were determined on a variable heat Gallenkamp melting point
apparatus (temperature range 20 – 350 °C) equipped with a laboratory thermometer, and are
uncorrected.
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IR υmax 2943 – 2810 (CH), 2096 (N≡N), 1451, 1281 (C–N), 1115; 1H NMR (300 MHz, CDCl3) δ
3.34 (t, J = 6.3 Hz, 2H), 2.55 (t, J = 6.3 Hz, 2H), 2.43 (br t, J = 6.2 Hz, 4H), 1.57 (p, J = 6.2 Hz,
4H), 1.43 (ddd, J = 9.0, 6.2, 2.2 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 57.8, 54.6, 48.4, 25.7,
24.3.
5.2.0.7 1-(3-Azidopropyl)piperidine (4b′).
Compound 4b′ was obtained as a pale yellow oil (273 mg, 70% yield) using the method already
described for 4b.The NMR data was found to match the cited literature.138
IR υmax 2933 – 2799 (CH), 2093 (N≡N), 1445, 1278 (C–N), 1123; 1H NMR (300 MHz, CDCl3) δ
3.33 (t, J = 6.8 Hz, 2H), 2.37 (td, J = 7.9, 6.7 Hz, 6H), 1.79 (p, J = 6.9 Hz, 2H), 1.59 (td, J = 10.8,
5.6 Hz, 4H), 1.41 (dd, J = 12.2, 7.2 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 56.2, 54.6, 49.8, 26.4,
26.0, 24.4.
5.2.0.8 1-(2-Azidoethyl)pyrrolidine (4c).
Compounds 4c and 4c′ were synthesized by the same method the corresponding azido mesylates
3a and 4a′ by adapting a literature method as follows:123 to a stirred solution of methane sulfonate
3a (500 mg, 3.03 mmol) in THF (15 mL) were added K2CO3 (1250 mg, 9.09 mmol) and
pyrrolidine (0.21 mL, 2.53 mmol) at 0°C. The resulting mixture was allowed to warm to room
temperature and then heated at reflux overnight. The reaction mixture was diluted with DCM (15
mL), the K2CO3 was removed by filtration and the excess organic solvent was evaporated to
obtain a crude product that was purified by silica gel column using 50% EtOAc/Hex to afford 4c
as a pale yellow oil (204 mg, 64%). The NMR data for 4c was consistent with the same compound
reported in the literature.139
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IR υmax 2933 (CH), 2093 (N≡N), 1278 (C–N); 1H NMR (300 MHz, CDCl3) δ 3.38 (t, J = 6.4 Hz,
2H), 2.67 (t, J = 6.4 Hz, 2H), 2.56 – 2.52 (m, 4H), 1.79 (td, J = 6.4, 3.1, 4H); 13C NMR (75 MHz,
CDCl3) δ 54.9, 54.2, 50.2, 23.5.
5.2.0.9 1-(3-Azidopropyl)pyrrolidine (4c′).
Compound 4c′ was prepared using the experimental procedure already described above to afford a
pale yellow oil (261 mg, 73% yield).
Yield 73%, IR υmax 2961 – 2789 (CH), 2093 (N≡N), 1456, 1276 (C–N), 1147; 1H NMR (300
MHz, CDCl3) δ 3.36 (t, J = 6.8 Hz, 2H), 2.57 – 2.45 (m, 6H), 1.87 – 1.72 (m, 6H); 13C NMR (151
MHz, CDCl3) δ 54.2, 53.3, 49.7, 28.4.4, 23.4; MS (ESI+) 155.1297 calculated for C7H14N4 [M +
H]+, found 155.1297 (100%, 0.00 ppm), 84.0182 (40%).
5.2.1.0 2-Azido-N,N-diethylenamine (4d).
Compound 4d was synthesized from 3a using the same methods already described for 4b to obtain
a colourless oil (189 mg, 48%). The 1H NMR spectra was found to be similar with one reported in
the literature.140
IR υmax 2947 – 2791 (CH), 2092 (N≡N), 1453, 1253 (C–N); 1H NMR (300 MHz, CDCl3) δ 3.29
(t, J = 6.3 Hz, 2H), 2.66 (t, J = 7.4 Hz, 2H), 2.57 (q, J = 6.1 Hz, 4H), 1.04 (t, J = 7.1 Hz, 6H); 13C
NMR (75 MHz, CDCl3) δ 52.1, 49.5, 47.2, 11.8.
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5.2.1.1 3-Azido-N,N-diethylpropan-1-amine (4d′).
Compound 4d′ was prepared as in 4d to afford a colourless oil (129 mg, 36% yield).
IR υmax 2942 (CH), 2097 (N≡N), 1343 (C–N), 1169; 1H NMR (300 MHz, CDCl3) δ 3.34 (t, J =
6.8 Hz, 2H), 2.52 (ddd, J = 8.0, 7.3, 5.0 Hz, 6H), 1.73 (p, J = 6.8 Hz, 2H), 1.03 (t, J = 7.3 Hz, 6H);
13C NMR (75 MHz, CDCl3) δ 49.8, 46.8, 31.8, 29.3, 11.5; MS (ESI+) 157.1454 calculated for
C7H16N4 [M + H]
+, found 157.1446 (-5.09 ppm).
5.2.1.2 4-(2-Azidoethyl)morpholine (4e).
Compound 4e was also prepared similarly to 4d and the product was obtained as a colourless oil
(271 mg, 69% yield).
IR υmax 2933 – 2789 (CH), 2093(N≡N), 1276 (C–N), 1147; 1H NMR (300 MHz, CDCl3) δ 3.73 (t,
J = 4.8 Hz, 4H), 3.35 (t, J = 6.4 Hz, 2H), 2.60 (t, J = 6.0 Hz, 2H), 2.51 (t, J = 4.8 Hz, 2H); 13C
NMR (75 MHz, CDCl3) δ 66.9, 57.6, 53.6, 47.9.
5.2.1.3 4-(3-Azidopropyl)morpholine (4e′).
Compound 4e′ was prepared in a similar fashion to 4d to recover a product as a colourless oil (268
mg, 68% yield).141
IR υmax 2947 – 2810 (CH), 2096 (N≡N), 1451, 1281 (C–N), 1115, 1069 (COC); 1H NMR (300
MHz, CDCl3) δ 3.71 (t, J = 4.5 Hz, 4H), 3.35 (t, J = 6.7 Hz, 2H), 2.50 – 2.32 (m, 6H), 1.77 (p, J =
6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 66.9, 55.6, 53.6, 47.5, 25.9.
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Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.38 (d, J = 2.1 Hz, 1H overlapping), 7.35 (d, J = 2.0 Hz, 1H
overlapping), 7.16 – 6.90 (m, 8H), 6.44 (d, J = 5.5 Hz, 1H), 4.57 (d, J = 3.1 Hz, 2H), 4.41 (t, J =
6.9 Hz, 2H), 3.77 (t, J = 6.4 Hz, 2H), 3.18 (s, 4H), 2.20 (p, J = 5.7 Hz, 2H); 13C NMR (75 MHz,
CDCl3) δ 151.1, 150.6, 147.6, 143.8, 135.4, 134.1, 130.1, 129.5, 128.0, 126.6, 125.7, 123.1, 121.9,
121.4, 119.7, 117.0, 99.3, 48.1, 46.9, 38.9, 32.1, 28.3; MS (ESI+) 495.2065 calculated for
C29H27ClN6 [M + H]
+, found 495.2067 (0.40 ppm).
5.3 In vitro antimalarial activity investigations.
The biological analysis of the test compounds was performed by the Professor Peter Smith in
Division of Pharmacology, University of Cape Town. Reported, herein, was the only received
data by the time of writing a thesis and additional data is expected once the ongoing tests have
been finalised.
5.3.1 Quantitative assessment of antiplasmodial activity.
The antiplasmodial activity of 6b – 6i were carried out on asexual erythrocyte stages of a
continuously maintained culture of NF54, a CQ-sensitive strain of P. falciparum, by a modified
literature method of parasite lactate dehydrogenase assay (pLDH).131,133 Briefly, the compounds
were prepared to a 20 mg/mL stock solution or a suspension in DMSO and sonicated to enhance
the solubility. Serial dilutions of stock solutions were carried out in triplicate in a 96-well plate
using a multichannel pipette and the compounds were tested on a concentration range of 1000
µg/mL and 0.2 ng/mL. CQ was used as a reference compound while DMSO solvent was a blank.
Additional positive controls such artesunate standard antimalarial drug and MMV390048
currently in the clinical trials were included with triazole-linked chloroquinoline derivatives test
compounds. The 50% inhibition concentration value of parasite growth (IC50) for each compound
was deduced from a non-linear full-dose response curve performed by Graph Pad Prism v.4.0
software. Data were collected using a microplate reader and analyzed as described above The IC50
activity values are shown in table 5.3.0.1.
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